Post-earnings recap
Reported
Thu, Feb 28, 2013
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a loss that was slightly worse than expected, leading to a 1.12% drop in stock price. The lack of revenue figures and forward guidance adds to investor uncertainty. The company's challenges in achieving profitability may weigh on future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.46 | N/A | -3.14% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current financial landscape. They did not provide future guidance, indicating uncertainty in upcoming performance.
Management did not provide specific guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability.